Edwards Lifesciences Corp (EW)

Nov 9, 2026

Edwards Lifesciences VP Donald Bobo Jr. sold 48,900 shares of the company's stock for approximately $5.04 million on November 9, 2026, under a pre-arranged Rule 10b5-1 trading plan. This transaction significantly reduced his holdings by 68.2%, leaving him with 22,798 shares. The company recently reported strong quarterly earnings, beating analyst estimates, and the stock traded up 2.5% following the news.

Nov 7, 2026

Boston Trust Walden Corp reduced its stake in Edwards Lifesciences Corporation (NYSE:EW) by 5.3% in the third quarter, selling 13,624 shares while retaining a substantial holding valued at over $21 million. This reduction occurred despite other institutional investors, like Assenagon Asset Management S.A., increasing their positions. Edwards Lifesciences reported strong Q3 earnings, beating analyst estimates with EPS of $0.80 and revenue of $1.72 billion, leading to a "Moderate Buy" consensus rating from analysts with an average price target of $108.88.

Nov 6, 2026

Cardinal Health increased its fiscal 2027 non-GAAP EPS guidance to $12.80–$13, following a rise in first-quarter non-GAAP EPS to $3.26, despite a 28% decline in profit from its medical products division. The company's optimistic outlook is attributed to strong performance in pharmaceutical and specialty solutions, as well as other growth businesses. Additionally, Cardinal Health has renewed contracts representing nearly two-thirds of its enterprise revenue over the past year, including a binding letter of intent to renew its CVS pharmacy agreements through 2032.

Nov 5, 2026

Truist Financial has upgraded Edwards Lifesciences (NYSE:EW) from a "hold" to a "strong-buy" rating. This upgrade follows Edwards Lifesciences' strong quarterly earnings, where the company surpassed analyst expectations for both earnings per share and revenue, demonstrating 10.5% year-over-year revenue growth. The company also saw positive clinical trial results for its PASCAL tricuspid repair system and TAVR for moderate aortic stenosis, contributing to a "Moderate Buy" consensus rating and an average price target of $101.88 across analysts.

Nov 5, 2026

Associated Banc Corp recently acquired 10,415 shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH), valued at approximately $925,000, as disclosed in its latest 13F filing. Zimmer Biomet reported better-than-expected third-quarter earnings and revenue, leading to a raised 2026 outlook, despite ongoing challenges with weak knee sales and margin pressure. Institutional investors now own 88.89% of the medical equipment provider's stock, with analysts generally maintaining a "Hold" rating.

Nov 4, 2026

Edwards Lifesciences (NYSE: EW) reported strong third-quarter 2026 results, with sales of $1.72 billion, an 11.2% increase, driven by its structural heart portfolio including TAVR and TMTT therapies. The company raised its full-year sales growth guidance to approximately 11.5% and adjusted EPS guidance to $2.97-$3.05. Management highlighted significant progress in clinical, regulatory, and commercial priorities, including multiple therapy approvals and new clinical data, reinforcing confidence in long-term growth.

Nov 4, 2026

Edwards Lifesciences presented positive results from two randomized trials at the annual TCT meeting, influencing the debate on valve disease intervention. The PROGRESS trial favored early aortic valve replacement in moderate narrowing patients, reducing deaths and heart failure events. A separate CLASP II TR study demonstrated the PASCAL system's effectiveness for leaky tricuspid valves, improving health status compared to medical therapy alone.

Nov 3, 2026

Edwards Lifesciences Corp. (EW) shares rose 2.07% to $95.19 on Tuesday, marking its second consecutive day of gains. The stock outperformed the broader market, as the S&P 500 Index increased 0.36% while the Dow Jones Industrial Average fell 0.38%.

Nov 2, 2026

Edwards Lifesciences Corp. (EW) shares advanced 1.36% to $93.26 on Monday, performing well individually but still underperforming compared to its competitors. The stock closed 3.15% below its 52-week high of $96.29, which was reached on July 7th. This occurred during a mixed trading session where the Dow Jones Industrial Average rose 0.41% and the S&P 500 Index fell 0.51%.

Nov 2, 2026

Johnson & Johnson presented findings from three clinical analyses suggesting lower mortality rates in patients undergoing high-risk percutaneous coronary intervention (HRPCI) with Impella heart pump support. These observational studies, involving 1,379 patients across the US and Europe, reported varied mortality outcomes at different intervals, numerically lower than figures from the CHIP-BCIS3 study. However, the company cautions that due to the observational nature and differences in study designs, these findings do not establish a causal link, with definitive evidence expected from the ongoing PROTECT IV randomized controlled trial in 2027.

Nov 2, 2026

Abbott has initiated a pivotal clinical trial for its investigational Cephea mitral valve system, a device designed to replace diseased mitral valves and restore normal blood flow. The Cephea system, acquired in 2019, is distinct from Abbott's Tendyne device as it is delivered through a vein in the leg. This trial is enrolling up to 585 patients across the U.S., Canada, and Europe to assess the device's efficacy in individuals with moderate-to-severe mitral regurgitation or calcified mitral valves.

Oct 30, 2026

Edwards Lifesciences Corp. (EW) stock fell 2.57% to $92.01 on Friday, underperforming the broader market as the S&P 500 Index and Dow Jones Industrial Average also declined. This drop ended a four-day winning streak for the company's shares.